Mojoon review
Graded on whether a price is published, checkable, and still true at month two — how we grade · how we verify prices
Mojoon charges $350 a month for compounded semaglutide, and tells you the price will rise as your dose does. Its published terms are an unfinished draft with a note to the writer in them.
$350 is month one. The same page says the price is adjusted every month as the dose rises, and the published range runs to $520 with no dose-by-dose breakdown.
- Advertised $1000, actually $350
- Month-to-month price published
- States published: AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY
- FDA warning letters: 0 of 0 matched
- Prices read September 2026
Read first-hand, not from a feed.
Distinct plans priced.
This link pays us nothing. It's here because the price is checkable.
The verdict
A Chinese-language seller that is clearer than most about the one thing sellers hide — it says in writing that the monthly price climbs with the dose. It also calls a compounded drug FDA-approved, publishes a contract that was never finished, and gives three different answers about how many states it serves.
This link pays us nothing. It's here because the price is checkable.
Quick facts
Key facts
- Compounded semaglutide
- $350 to $520 a month, by dose
- Compounded tirzepatide
- $390 to $490 a month
- Does the price rise with the dose?
- Yes, and the seller says so in writing
- Dose-by-dose prices
- Not published
- Company
- Mojoon Inc, Covina, California
- Who prescribes
- Beluga Health, P.A.
- Pharmacy
- Not named
- Terms of service
- Published unfinished, with a note to the writer in place of the terms
- States
- 48, 49 and 51 on four different surfaces
- FAQ page
- Twelve headings, zero answers
Pros and cons
What we like
- It states in writing that the monthly price is adjusted upward as the dose increases — a disclosure almost nobody in this market makes.
- Both injectable pages say the course is reckoned by the month, so the monthly figure means something.
- The legal entity and a California street address are published in the terms.
- The prescribing group, Beluga Health, P.A., is named.
- The About page publishes an enumerated state list rather than only a count.
- The refund page allows cancellation at any time before the medication ships.
- Its terms disclose the operator's second brand rather than hiding the relationship.
What could be better
- The published terms are an unfinished draft containing an instruction to paste in the real terms.
- No governing law, payment terms or arbitration clause is published anywhere as a result.
- The oral semaglutide page describes a compounded product as FDA-approved.
- No page states how long an oral course lasts, so its price cannot be compared to anything.
- The state count contradicts itself across four surfaces: 48, 48, 49 and a list of 51.
- The FAQ page publishes twelve section headings and no answers at all.
- No pharmacy is named anywhere on the site.
- No dose-by-dose price table exists, so the published range cannot be planned against.
What it is
Mojoon is a telehealth seller aimed at Chinese-speaking patients in the United States; the entire consumer site is in Chinese. It sells compounded semaglutide and tirzepatide as weekly injections blended with B12, an oral semaglutide, and two non-GLP-1 products. The prescribing is done by a named outside group, Beluga Health, P.A., which is the usual arrangement in telehealth prescribing.
The company is named: Mojoon Inc, with a street address in Covina, California, published in its terms. Its terms also disclose that the same operator runs a second brand on another domain.
Its FAQ page is a shell. It publishes twelve section headings and not one answer — and the answers are not hidden behind a control that failed to open, they are simply absent from the page. One of the empty sections is the one headed consultation and prescription pricing.
Every price we found
| Plan | Advertised | What you actually pay | The gap | Read on |
|---|---|---|---|---|
| Compounded semaglutide with B12, weekly injectionThe course is reckoned by the month with a required monthly follow-up. The published range runs to $520 and the seller states the price rises with the dose. | $1000 | $350 | September 2026 | |
| Compounded tirzepatide with B12, weekly injectionAlso reckoned by the month. The range runs to $490, and this page gives no explanation of what moves the price across it. | $1000 | $390 | September 2026 |
This link pays us nothing. It's here because the price is checkable.
What it actually costs
Compounded semaglutide is published as a range, $350 to $520 a month, and the page says outright that the price is adjusted every month as the dose goes up.
That sentence — the medication price is adjusted monthly according to the dose increase — is worth more than it looks. Most sellers on this roster print one number and let you discover the titration surcharge later. Mojoon tells you in advance. What it does not publish is which dose costs what, so you know the direction of travel and the ceiling but not the steps. Tirzepatide is quoted the same way, $390 to $490, and that page carries no explanation at all for what moves the price across its range.
Both injectable pages say the course is reckoned by the month and that a monthly follow-up consultation is required, which is what makes these monthly figures honest. The $1,000 struck through beside each price is a comparison figure, not something anyone is charged.
The oral semaglutide page calls the product FDA批准 — FDA-approved. Compounded drugs are not FDA-approved, and that page also never says how long its course lasts.
The oral product is sold at $400 a course, and we have deliberately not published that as a monthly price anywhere on this page. Across ten pages read in full, the site never states how long an oral course runs — not in days, weeks, doses or vials — so nobody can say what a month of it costs. Its only cadence statement is that you take it once a day. It is also the page that describes a compounded preparation as approved, which is exactly the claim that the difference between compounded and brand medication turns on.
A course is a subscription rather than a one-off — the refund page tells you that you may cancel it at any time before the medication ships — but the site never states a renewal interval or an auto-renew term for any product, and the word for subscription appears exactly once across the whole site.
Who it's wrong for
- Anyone who does not read Chinese. The consumer site is entirely in Chinese and there is no English version of the pricing.
- Anyone budgeting on the entry price. The company states that the monthly charge rises with the dose, and publishes no dose-by-dose table.
- Anyone relying on the oral product's regulatory status. Its page calls a compounded drug FDA-approved, which it is not.
- Anyone who wants to know what they agreed to. The published terms contain a drafting note asking for the real terms to be pasted in, so governing law, payment terms and arbitration are referenced but never published.
- Anyone checking whether their state is covered. The homepage and the intake app say 48 states, the About page says 49, and the list behind the About page's own control has 51 entries.
Medications available
- Compounded semaglutide with B12Compounded$350 to $520 a month
Once weekly. The price rises with the dose by the seller's own statement.
- Compounded tirzepatide with B12Compounded$390 to $490 a month
Once weekly.
Is Mojoon legit?
Mojoon is operated by Mojoon Inc, 861 South Village Oaks Drive, Suite 204, Covina, California, 91724. We read that off the company’s own terms and conditions on September 2026.
What that means
A known-positive control passed in the same run, so a real match would have surfaced. A letter would be worth knowing about; it would not by itself disqualify a seller.Pharmacy, prescribers and safety checks
- Legal entityMojoon Inc, with a California street address
- Who prescribesBeluga Health, P.A.
- Pharmacy namedNot disclosed
- Drug formCompounded — though the oral page calls it FDA-approved
- Governing lawNot published; the terms were never finished
- Billing intervalMonthly for the injectables; never stated for the oral product
- CancelingAt any time before the medication ships, with a refund
- States servedAn enumerated list of fifty-one, contradicted by counts of 48 and 49
Common questions
How much does Mojoon cost per month?
Compounded semaglutide is published as $350 to $520 a month and tirzepatide as $390 to $490. Both product pages say the course is reckoned by the month and that a monthly follow-up consultation is required.
Why does the Mojoon price change?
Because the dose does. The semaglutide page states that the medication price is adjusted monthly according to the dose increase, so $350 is the starting month rather than a held rate. The site publishes no table showing which dose costs what, and the tirzepatide page offers no explanation of its range at all.
Is Mojoon's oral semaglutide FDA-approved?
No. Its page says FDA批准 — FDA-approved — but compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality. That page also never states how long a course of the oral product lasts, so its price cannot be compared with a monthly figure.
Who owns Mojoon?
Mojoon Inc, with a street address in Covina, California, published in its terms and conditions. The prescribing group is named separately as Beluga Health, P.A. No pharmacy is named anywhere on the site.
Which states does Mojoon serve?
It gives three answers. Its homepage and its intake app both say 48 states, its About page prose says 49, and a list revealed by that same page's own control enumerates all fifty states and the District of Columbia. We counted the list against a canonical list of the states rather than by splitting on commas.
What do Mojoon's terms say?
Very little that is binding. The published document contains an unfinished drafting note asking for the current version to be pasted in and merged, standing where the substantive terms should be. Limitation of liability, payment terms, arbitration and governing law are referred to but published nowhere.
Why we gave Mojoon a C
Read the full grading rationale
Mojoon sells to Chinese-speaking patients in the United States, and on the two injectables it is clearer than most: each product page prints a price range, says the course is reckoned by the month, and adds the sentence almost no seller writes down — "the medication price is adjusted monthly according to the dose increase." So $350 for compounded semaglutide is honestly month one, and the company tells you it will rise. Three things pull it down to a C. Its published terms contain an unfinished drafting note where the contract should be, asking for the current version to be pasted in so it can be merged — so limitation of liability, payment terms, arbitration and governing law are referenced by the document and published nowhere. The oral semaglutide page describes a compounded product as FDA批准 — FDA-approved — which compounded drugs are not, and that page also never states how long its course lasts, the one product where the month is left undefined. And the company gives three different answers about where it operates: 48 states on the homepage and inside its intake app, 49 in its About prose, and an enumerated list of all 50 plus the District of Columbia behind a control on the same About page. Its FAQ page publishes 12 section headings and zero answers, including the one headed consultation and prescription pricing. The prescribing group is named — Beluga Health, P.A. — and no pharmacy is.
What that means
Screening is by entity — the company’s own domain plus the address it publishes — never by brand name, because a brand name matches every namesake. Where a company publishes no address, the address half of that match is never exercised, and the result is recorded as the weaker kind of absence rather than a clean record. A known-positive control passed in the same run, so a real match would have surfaced. A letter would be worth knowing about; it would not by itself disqualify a seller.How we reviewed Mojoon
- We read ten pages in full with a scroll pass, in Chinese, and counted the specific terms that would establish a billing interval — the words for month, monthly, subscription, automatic and renewal — rather than relying on an impression of the page.
- The oral semaglutide page was re-fetched and counted character by character: across 2,259 characters of visible text the word for a treatment course appears once, in the price line, and the words for month and monthly appear zero times. That is why we publish no monthly figure for it.
- We searched the FAQ page's full HTML, not just its visible text, to check whether its missing answers were hidden rather than absent. They are absent: the headings are plain headings with no accordion wrapper and no answer text anywhere in the markup.
- The state list was opened with its own control on the About page and counted against a canonical list of the fifty states, then compared with the counts printed on the homepage, the About prose and the intake app.
- We opened the intake twice at two different entry points to confirm the account gate was not a one-off. It gates at the first screen, and we did not create an account.
- The FDA warning-letter screen ran on the company's own domain and published address, with a known-positive and a known-negative control passing in the same run. It returned no candidate letters.
The 2 pages we read — all on
- %e5%8f%b8%e7%be%8e%e6%a0%bc%e9%b2%81%e8%82%bd semaglutide page
$1000 $350 – $520/疗程 司美格鲁肽疗程按月计算，需每月保持跟踪问诊 药物价格根据剂量增加而每月调整
- %e6%9b%bf%e5%b0%94%e6%b3%8a%e8%82%bd tirzepatide page
$1000 $390-$490/疗程 替尔泊肽疗程按月计算，需每月保持跟踪问诊
This link pays us nothing. It's here because the price is checkable.
Alternatives to Mojoon
| Provider | Grade | Cheapest price |
|---|---|---|
| TeleWellnessMD | CCaveat | $349.95/mo |
| Ro | BMinor gap | $349/mo |
| Alan Meds | BMinor gap | $315/mo |
| CeliaRx | CCaveat | $299/mo |
| MEDGm | BMinor gap | $299/mo |